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Platelets affect myocardial damage from ischemia/reperfusion. Redox-dependent
sphingosine-1-phosphate production and release are altered in diabetic platelets.
Sphingosine-1-phosphate is a double-edged sword for ischemia/reperfusion injury.
Therefore, we aimed to verify whether: (1) human healthy- or diabetic-platelets are
cardioprotective, (2) sphingosine-1-phosphate receptors and downstream kinases
play a role in platelet-induced cardioprotection, and (3) a correlation between
platelet redox status and myocardial ischemia/reperfusion injury exists. Isolated rat
hearts were subjected to 30-min ischemia and 1-h reperfusion. Infarct size was
studied in hearts pretreated with healthy- or diabetic-platelets. Healthy-platelets were
co-infused with sphingosine-1-phosphate receptor blocker, ERK-1/2 inhibitor, PI3K
antagonist or PKC inhibitor to ascertain the cardioprotective mechanisms. In platelets
we assessed (i) aggregation response to ADP, collagen, and arachidonic-acid, (ii)
cyclooxygenase-1 levels, and (iii) AKT and ERK-phosphorylation. Platelet sphingosine-
1-phosphate production and platelet levels of reactive oxygen species (ROS) were
quantified and correlated to infarct size. Infarct size was reduced by about 22% in
healthy-platelets pretreated hearts only. This cardioprotective effect was abrogated
by either sphingosine-1-phosphate receptors or ERK/PI3K/PKC pathway blockade.
Cyclooxygenase-1 levels and aggregation indices were higher in diabetic-platelets
than healthy-platelets. Diabetic-platelets released less sphingosine-1-phosphate than
healthy-platelets when mechanical or chemically stimulated in vitro. Yet, ROS levels
were higher in diabetic-platelets and correlated with infarct size. Cardioprotective effects
of healthy-platelet depend on the platelet’s capacity to activate cardiac sphingosine-1-
phosphate receptors and ERK/PI3K/PKC pathways. However, diabetic-platelets release
less S1P and lose cardioprotective effects. Platelet ROS levels correlate with infarct
size. Whether these redox alterations are responsible for sphingosine-1-phosphate
dysfunction in diabetic-platelets remains to be ascertained.
Keywords: cardioprotection, infarct size, ischemia/reperfusion, platelets, sphingosine-1-phosphate, type 2
diabetes mellitus
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INTRODUCTION
The role played by platelets in determining cardiac
ischemia/reperfusion (I/R) injury is not clear. Studies,
conducted in the nineties, suggested that healthy platelets
have cardioprotective properties. Indeed, healthy rat platelets
resulted protective against myocardial injury induced by I/R in
isolated rat hearts and by hypoxia/reoxygenation in cultured
adult rat cardiomyocytes (Yang et al., 1993, 1994, 1998, 1999;
Yang and Mehta, 1994; Mehta et al., 1999). Subsequently, in a
2002 study, Mirabet et al. (2002) infused pig platelets – collected
before or after coronary occlusion – into Langendorff rat hearts,
which were subsequently submitted to I/R. Only the pig platelets
collected after reperfusion enhanced I/R injury in rat hearts.
The authors concluded that the deleterious effect of platelets on
reperfused myocardium depends on their activation status.
Recent studies by Cohen and Downey group have shown
that P2Y12 receptor antagonists (e.g., Cangrelor, Ticagrelor)
targeting platelets may exert a cardioprotective effect. Since
the cardioprotective mechanism seems not attributable to
inhibition of platelet aggregation (Yang et al., 2013a,b; Cohen
and Downey, 2014, 2015), the authors suggest that patients
treated with these antagonists are benefiting from protective
“conditioning pathways” triggered by factors released by platelets.
Indeed, these conditioning pathways are very similar to those
activated by brief periods of intermittent non-lethal ischemia,
before or after a prolonged ischemia, that are the well-
known phenomena of pre- and post-conditioning (Cohen
and Downey, 2015; Pagliaro and Penna, 2015; Penna et al.,
2015). These conditioning phenomena induce the activation
of protective pathways and a consequent reduction of I/R
injury.
Many endogenous molecules could induce conditioning
cardioprotection, eliciting specific pathways (Cohen and
Downey, 2015; Pagliaro and Penna, 2015; Penna et al., 2015).
Platelets are known to release a plethora of molecules, which
mediate platelet effects in a variety of conditions, including
cardioprotection against I/R injury (Yang et al., 1993; Penna
et al., 2005, 2015). A platelet-derived cardioprotective molecule
is Sphingosine 1-phosphate (S1P), a bioactive lipid mediator
abundantly carried and stored by platelets, whose production
and release seem redox-dependent and related to thromboxane
formation, but mechanisms are poorly understood (Yatomi et al.,
1995; Tani et al., 2005; Ulrych et al., 2011; Ono et al., 2013; Russo
et al., 2017).
S1P exerts its function through five specific cell surface
receptors (S1PRs) on target organs (Tani et al., 2005; Vito
et al., 2016) and is a double-edged sword: S1P is a potent
proinflammatory and mediator of allergic diseases (Maceyka
and Spiegel, 2014; Kulinski et al., 2016; Vito et al., 2016), but
it is also a potent protectant against I/R injury (Vessey et al.,
2009). The S1P cardioprotection seems mediated by interaction
with types 1–3 S1PRs, with subsequent activation of the so-
called RISK/SAFE pathways (Vessey et al., 2009; Cohen et al.,
2016). However, S1PR1 does not appear cardioprotective in vivo,
whereas a combination of S1PR2 and S1PR3 activation mediates
cardioprotection (Means et al., 2007). Nevertheless, these studies
revealed that S1P is an important mediator of cardioprotection
and could induce either pre- or post-conditioning.
Several pathological conditions, including type 2 diabetes
mellitus (T2DM), reduce the efficacy of ischemic conditioning
strategies (Ferdinandy et al., 2014). However, unlike
cardioprotection induced by ischemic conditioning, P2Y12
antagonist-induced conditioning can result in significant
attenuation of I/R injury also in diabetic animals (Bell et al.,
2015). These last results open an interesting scenario on the
role of platelets in cardioprotection. Therefore, in-depth studies
on platelet characteristics and their role in cardioprotection are
necessary.
Of note, the S1P dynamic is profoundly altered in diabetic
conditions (Fox et al., 2011) and diabetes is indicated as
a “pro-thrombotic state” in which, among other alterations,
oxidative stress and platelet hyperactivity play crucial roles in
the cardiovascular complications (Jung et al., 2015). Therefore,
one can wonder: are diabetic platelets cardioprotective and can
reduce I/R damage? Although it is well known that diabetic
platelets display a certain degree of activation (Watala et al.,
2005; Jung et al., 2015), to the best of our knowledge, no studies
ascertained whether the platelet-dependent cardioprotective
properties are altered in the platelets of T2DM subjects.
Therefore, after a thorough study of platelet characteristics
derived from healthy and T2DM subjects, we aimed to verify
whether:
(1) Human healthy and diabetic platelets are cardioprotective in
an isolated rat heart model;
(2) S1P and RISK-pathways play a role in platelet-induced
cardioprotection;
(3) a correlation between platelet redox status (an index of
platelet dysfunction) and myocardial I/R injury exists.
To these aims, blood samples were collected from voluntary
healthy subjects and from T2DM patients. Platelet samples
were analyzed for aggregatory aspects, ROS production and S1P
release in vitro or were used to be infused in isolated hearts before
being subjected to I/R protocols either in the absence or in the
presence of S1P receptor blocker and RISK-pathway antagonists.
MATERIALS AND METHODS
Subjects and Platelet Preparation
The study was performed on platelets obtained from 35 healthy
volunteers and 16 type 2 diabetes mellitus (T2DM) patients.
Healthy subjects were not on any antiplatelet therapy nor
did they have any history of cardiovascular disease, metabolic
syndrome or diabetes. Patients affected by T2DM were recruited
among those attending the Metabolic Disease and Diabetes
Unit of the San Luigi Gonzaga Hospital in Orbassano (Turin);
six of them were at first diagnosis, the others were poorly
controlled with glycated hemoglobin A1c (HbA1c) > 7.5%
even though on antidiabetic drugs. All subjects were without
previous cardiovascular events and antiplatelet drugs in the
previous 2 weeks. The totality of subjects gave informed consent
before the investigation and the Ethics Committee of San Luigi
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Hospital approved the study, in accordance with the Declaration
of Helsinki. The present study is a “case-control study” that
raises potential issues of bias due to patient- and voluntary-
donor selection. However, data collection was performed by
blinded operators on the origin of platelets. Therefore, there is
no subjectivity implied in the assessment or bias under these
conditions.
Blood samples were collected from the antecubital vein and
laboratory measurements were performed after a 12-h overnight
fast. Biochemical parameters, including assessment of fasting
glucose, total cholesterol, triglycerides, low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol
and HbA1c as well as platelet number were measured using
routine laboratory methods, performed by the central laboratory
of our Hospital.
For studies concerning platelet function, a venous blood
sample was withdrawn without stasis after an overnight fast,
and anticoagulated with 3.8% sodium citrate, pH 7.4 (vol/vol:
1/9) for aggregation studies in platelet-rich plasma or with a
citrate-dextrose solution (ACD; v/v, 1/6) for experiments on
washed platelets. Platelet-rich plasma was obtained by using
Platelet Function Centrifuge (BioData Corporation, Horsham,
PA, United States) designed to provide a rapid separation
of platelet-rich plasma by a centrifugation for 30 s and of
platelet-poor plasma by a further centrifugation for 120 s.
To prepare washed platelets, ACD-anticoagulated platelet-rich
plasma, obtained by centrifugation at 100 × g for 20 min,
underwent further centrifugation at 2000 × g for 10 min and
pellet was washed two times at 37◦C in HEPES-Na buffer
(in mmol/L) (10 HEPES Na, 140 NaCl, 2.1 MgSO4, 10 D-
glucose, pH 7.4).
Platelet Aggregation Studies
Platelet aggregation studies were carried out in both platelet-rich
plasma and whole blood. Aggregation tests in platelet-rich plasma
followed light-scattering changes as described by Born (1962)
using an eight-channel aggregation system (Platelet Aggregation
Profiler, Model PAP-8, BioData Corporation) and were induced
by ADP (10 µmol/L), arachidonic acid (AA, 1 mmol/L), and
collagen (4 mg/L). Each aggregation test was recorded for 5 min
and reported as percent of maximal aggregation.
For platelet aggregation in whole blood by impedance method,
citrated blood samples were diluted 1:1 with physiologic saline
and the tests were performed in a Chrono-Log Whole Blood
Aggregometer, Model 500 at a constant stirring of 1000 rpm.
Aggregation was induced with ADP (20 µmol/L), collagen
(4 mg/L) or AA (1 mmol/L) and was recorded for 8 min.
The maximum increase in resistance, expressed in ohms, was
calculated.
Reactive Oxygen Species (ROS) Assay
Intracellular ROS were evaluated in washed platelets by using
the sensitive fluorescent indicator DCF-DA oxidized by H2O2 to
the highly fluorescent DCF (Eruslanov and Kusmartsev, 2010).
Washed platelets (6 × 107 ml−1) were exposed to 10 µmol/L
cell permeant reagent DCF-DA and DCF fluorescence was
measured at basal and after stimulation with AA (100 µmol/L)
added just before measuring fluorescence. To examine specific
signaling in basal ROS generation, platelets were preincubated for
20 min with the NADPH-oxidase inhibitors APO (10 µmol/L)
or DPI (10 µmol/L), or the cyclooxygenase-1 (COX-1) inhibitor
indomethacin (INDO, 100 µmol/l) (Gerrits et al., 2010; Barale
et al., 2017).
Fluorescence was measured over a 60-min period at 1-min
intervals using a plate fluorometer (GloMax-Multi Detection
System, Promega Corporation, Madison, WI, United States)
fitted with 490 nm excitation and 520 nm emission filters.
Fluorescence per minute was calculated for each sample.
Platelet S1P Assay
Washed platelets (500 µl for each sample containing 150 × 106
platelets) were used to measure S1P release both in the absence
(resting platelets) and in the presence of a stir bar put into the
cuvette (stirring platelets) (Lee et al., 2016). For samples subjected
to stirring, the stir bar inside the sample is spun, thus stirring
the washed platelets to a 1200 rpm speed at 37◦C. An eight-
channel optical aggregometer was used (Platelet Aggregation
Profiler, Model PAP-8, BioData Corporation) at this end. After
8-min incubation with or without collagen (4 mg/l), all samples
were submitted to repeated freeze-thaw cycles to let out the
inside components, centrifuged at 3000 rpm for 20 min and
supernatants were collected for S1P measurement.
S1P levels were determined by using an Enzyme-Linked
Immuno-adsorbent Assay according to manufacturer
instructions (Bioassay Technology Laboratory, Shanghai,
China). Standard curve range was 5–1500 ng/l, the sensitivity of
the kit was 2.34 ng/l, and intra- and inter-assay CV were <8%
and <10%, respectively.
Western Blot Analysis in Platelets
To assess the activation state of platelets, we detected the
phosphorylation/activation of phosphatidylinositol-3-kinases
(PI3K) and extracellular signal-regulated kinases (ERK) in
response to platelet agonists: washed platelets were stimulated
by collagen (4 mg/L) or AA (100 µmol/L) for 8 min and the
amounts of AKT, and pAKT, and ERK-2, pERK-1/2 were
evaluated, respectively.
Cyclooxygenase-1 expression was also determined. Washed
platelets samples were centrifuged and pellets solubilized in
Laemmli buffer and processed as previously described (Russo
et al., 2007). Membranes were incubated with rabbit anti-AKT,
mouse anti-ERK-2 (Cell Signaling, Danvers, MA, United States),
rabbit anti-phospho-Akt-Ser-473, mouse anti-phospho-ERK-
1/2-Tyr-204, or mouse anti-COX-1 (Santa Cruz Biotechnology).
As secondary antibodies, we used goat anti-mouse (Jackson
Immuno Research Lab., West Grove, PA, United States) or goat
anti-rabbit (Cell Signaling) antibodies conjugated to horseradish
peroxidase. Blots were scanned and densitometrically analyzed
by the image analyzer 1D Image Analysis software (Kodak,
Rochester, NY, United States).
Animals
Male Wistar rats (n = 75; 4–5-month-old, body weight 400–
450 g, Harlan Laboratories Udine, Italy) were used for the ex vivo
Frontiers in Physiology | www.frontiersin.org 3 July 2018 | Volume 9 | Article 875
fphys-09-00875 July 6, 2018 Time: 17:34 # 4
Russo et al. Human Platelet Cardioprotective Effects
experiments as specified below. Animals were housed under
controlled conditions with free access to standard rat diet and
tap water. Rats received humane care in compliance with the
European Directive 2010/63/EU on the protection of animals
used for scientific purposes. The animal protocols followed in
this study were approved by the local “Animal Use and Care
Committee.” In this study, six hearts were discarded due to the
very low left ventricular developed pressure or other technical
issues after connection to the perfusion line.
Isolated Heart Preparations
Rats were anesthetized, heparinized (800 U/100 g b.w., i.m.),
and hearts were rapidly excised, placed in an ice-cold buffer
solution, and weighed. Isolated hearts were attached to the
perfusion apparatus and retrogradely perfused with oxygenated
Krebs–Henseleit buffer solution (KHS) containing (in mM): 127
NaCl, 5.1 KCl, 17.7 NaHCO3, 1.26 MgCl4, 1.5 CaCl2, 11 D-
glucose (pH 7.4; 37◦C; 95% O2/5% CO2). Hearts were kept in
a temperature-controlled chamber (37◦C), electrically paced at
280 b.p.m. The hearts were perfused in constant-flow mode
and to assess the preparation conditions, coronary perfusion
pressure and left ventricular pressure were monitored during all
experiments (Penna et al., 2005, 2012).
Experimental Groups
To verify the cardioprotective properties of washed PLTs
derived from healthy subjects (healthy-PLTs) or diabetic patients
(diabetic-PLTs), hearts were assigned to one of the experimental
groups described below on the basis of availability of the
platelet donor. In all groups, the hearts were subject to 30 min
stabilization, and 30 min of normothermic global ischemia
followed by 60 min reperfusion (I/R). Protocols are as follow
(Figure 1):
FIGURE 1 | Timeline of experimental protocols. Protocols of ischemia (black
boxes) and reperfusion (white boxes) in isolated rat hearts. After stabilization
(white boxes), Krebs-Henselite solution (KHS) was infused via a collateral line
alone or with addition of washed PLTs and/or inhibitors (gray boxes). Washed
platelets (PLTs) were given for 10 min before ischemia and inhibitors were
given 5 min before PLTs and were stopped at the end of the 10 min of infusion
of PLTs (total time infusion for inhibitors was 15 min). For further explanations,
see the text.
(1) In the I/R group (n = 7), after stabilization, only the I/R
protocol was performed (Bell et al., 2011);
(2) In the healthy-PLT group (n = 8) healthy subject washed
platelets diluted in KHS (healthy-PLTs, 3 × 107 ml−1) were
infused to the heart, via a collateral line, for 10 min at a flow
rate of 12 ml/h; then hearts were subjected to I/R protocol;
(3) In the diabetic-PLT group (n = 8) diabetic patient washed
platelets diluted in KHS (diabetic-PLTs, 3 × 107 ml−1) were
infused to the heart, via a collateral line, for 10 min at a flow
rate of 12 ml/h; then hearts were subjected to I/R protocol.
For groups 2 and 3, each rat heart was treated with the platelets
from a single donor and the platelet concentration and time
of infusion were similar to those used by Yang et al. (1993).
This relatively low concentration of platelets reduces the risk of
capillary plugging and loss of myocardial function.
Since only healthy-PLTs affected significantly infarct size (see
section “Results”), the following healthy-PLT+inhibitors groups
were studied. In these groups, hearts were subjected to infusion
of inhibitor alone for 5 min, then a co-infusion with healthy-PLT,
for 10 min as in group 2, was performed, and, finally, the hearts
underwent I/R protocol. Therefore, inhibitors were infused for a
total of 15 min:
(4) In the healthy-PLT+VPC group (n = 5), to ascertain
the involvement of S1P receptors in healthy-PLT-induced
cardioprotective mechanisms, we used the S1P receptor
blocker VPC23019 (1 × 10−6 M) as S1P1/3 receptor
antagonist (Davis et al., 2005; Vessey et al., 2009);
(5) In the healthy-PLT+U0126 group (n = 5), to ascertain the
involvement of myocardial ERK1/2, we used the ERK1/2
antagonist, U0126 (60× 10−6 M) (Mochizuki et al., 2013);
(6) In the healthy-PLT+LY group (n = 5), to ascertain the
involvement of myocardial PI3K/AKT, we used the PI3K
antagonist, LY294002 (5× 10−5 M) (Penna et al., 2005);
(7) in the healthy-PLT+CHE group (n = 5), to ascertain
the involvement of myocardial PKC, we used the PKC
antagonist, Chelerythrine (1× 10−6 M) (Penna et al., 2017);
Inhibitors were also tested alone at the same concentrations
and for the same periods:
(8) In the VPC23019 group (n = 5): hearts were subjected
to infusion of VPC23019 for 15 min; then hearts were
subjected to I/R protocol;
(9) In the U0126 group (n = 4): hearts were subjected to infusion
of U0126 for 15 min; then were subjected to I/R protocol;
(10) In the LY294002 group (n = 4): hearts were subjected to
infusion of LY294002 for 15 min; then hearts were subjected
to I/R protocol;
(11) In the Chelerythrine group (n = 4): hearts were subjected
to infusion of Chelerythrine for 15 min; then hearts were
subjected to I/R protocol.
Infarct Size Assessment
In order to assess infarct size extension, a gravimetric method was
used in a blinded fashion. In briefly at the end of reperfusion,
hearts were rapidly removed from perfusion apparatus and the
left ventricular tissue was dissected into 2–3 mm circumferential
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slices. After 20 min of incubation at 37◦C in 0.1% solution of
nitro-blue tetrazolium in phosphate buffer, unstained necrotic
tissue was carefully separated from stained viable tissue and
weighed. The necrotic mass was expressed as a percentage of total
left ventricular mass, which was considered as risk area (Penna
et al., 2014, 2017).
Western Blot Analysis in Hearts
In additional experiments, immunoblot procedures and analyses
were conducted as previously described (Penna et al., 2012, 2014,
2017). Immediately after the hearts had undergone I/R (n = 4)
or PLT pretreatment (either healthy-PLTs, n = 8, or diabetic-
PLTs n = 5), the cardiac specimens were frozen in liquid nitrogen
before being stored at−80◦C until protein extraction. Myocardial
tissues of the above groups were homogenized in a frozen
RIPA lysis buffer (Sigma-Aldrich, St. Louis, MO, United States)
containing a mixture of protease inhibitors (1 mM of aprotinin,
20 mM of phenylmethylsulfonyl fluoride and 200 mM of sodium
orthovanadate). Subsequently, myocardial homogenates were
centrifuged at 15,000 × g for 25 min at 4◦C for debris removal.
Protein concentration was assessed using a Bradford reagent
following the procedure described by the manufacturer (Sigma-
Aldrich, St. Louis, MO, United States). Equivalent amounts
of proteins (80 µg) were loaded and electrophoresed on
SDS polyacrylamide gel and transferred to a polyvinylidene
difluoride membrane. Membranes were then incubated overnight
at 4◦C with primary antibodies mouse anti-phospho-ERK-1/2-
Tyr-204 (Santa Cruz Biotechnology) or mouse anti-ERK-1/2
(Cell Signaling, Danvers, MA, United States). As secondary
antibody, we used goat anti-mouse (Jackson Immuno Research
Lab., West Grove, PA, United States). Blots were scanned and
densitometrically analyzed by the image analyzer ID Image
Analysis software (Kodak, Rochester, NY, United States).
Chemicals
Collagen and arachidonic acid were purchased from Mascia
Brunelli Spa (Monza, Milan, Italy). The sources of the specific
antibodies are shown in the different sections. The other reagents
were obtained from Sigma (St. Louis, MO, United States) if not
differently specified.
Statistical Analysis
Data are expressed as mean ± SE. Statistical analysis was
performed with one-way analysis of variance (ANOVA) followed
by Student’s t-test or Newman–Keuls multiple-range test
depending on the experiments. P-value ≤ 0.05 was considered to
be significant. A linear fit is assessed between ROS production
and infarct size. A P-value < 0.05 was considered statistically
significant.
RESULTS
The characteristics of study participants are shown in Table 1.
Healthy volunteers and T2DM subjects were significantly
different for BMI (p < 0.0001), HbA1c (p < 0.0001), fasting
glucose (p < 0.0001), total cholesterol (p < 0.0001), triglycerides
TABLE 1 | Clinical characteristics, laboratory findings, and medications of healthy
and T2DM subjects.
Healthy
subjects
(n = 35)
T2DM
subjects
(n = 16)
p-value
M/F 17/18 7/9
Age (years) 53.0 ± 1 57.1 ± 2 0.08
BMI (kg/m2) 23.6 ± 0.2 31.6 ± 2 0.0001
HbAlc (%) 5.4 ± 0.1 11.3 ± 0.8 0.0001
Fasting glucose (mg/dl) 84.9 ± 2 320.5 ± 36 0.0001
Total cholesterol (mg/dl) 155.2 ± 4 193.9 ± 13 0.0001
HDL cholesterol (mg/dl) 52.0 ± 1 48.2 ± 2 0.074
Triglycerides (mg/dl) 105.0 ± 4 151.9 ± 22 0.005
LDL cholesterol (mg/dl) 85.7 ± 4 115.4 ± 10 0.002
SBP (mmHg) 120.6 ± 1 122.1 ± 8 0.786
DBP (mmHg) 78.5 ± 0.8 75.6 ± 2 0.093
Platelets (×l03/µl) 236.2 ± 5 243.9 ± 8 0.401
Insulin use – 6 (38%)
Oral antidiabetic medication use – 9 (56%)
Statin use – 10 (63%)
Antihypertensive drugs use – 11 (69%)
HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index;
SBP, systolic blood pressure; DBP, diastolic blood pressure.
(p < 0.005), and LDL cholesterol (p < 0.002). There were no
differences between the two groups with regard to age, HDL-
cholesterol, platelet number, systolic and diastolic blood pressure.
Platelet Characteristics
We first analyzed platelet (PLT) characteristics in both T2DM and
healthy subjects.
Platelet Aggregation Parameters Were Higher in
Diabetic-PLTs Than in Healthy-PLTs
Platelet aggregation parameters were studied in diabetic-PLTs
and in healthy-PLTs, in both platelet-rich plasma (Figure 2A)
and whole blood (Figure 2B) samples. As shown in Figure 2A,
in platelet-rich plasma, diabetic-PLTs, compared to healthy-PLTs,
showed significantly higher aggregation to ADP (p < 0.0001),
collagen (p < 0.0001), and AA (p < 0.0001). In particular,
in diabetic-PLTs, the aggregation was higher by about 35% in
response to ADP, 47% to collagen, and 30% to AA.
As shown in Figure 2B, in whole blood, diabetic-PLTs,
compared to healthy-PLTs, showed significantly higher
aggregation to ADP (p < 0.0001), to collagen (p < 0.005),
and AA (p < 0.0001). Specifically, in diabetic-PLTs, the
aggregation was higher by about 45% in response to ADP, 21% to
collagen, and 53% to AA.
S1P Release Was Lower in Diabetic-PLTs Than in
Healthy-PLTs
The release of S1P was measured in supernatants of washed
platelets in resting and stirring conditions (Figure 3). In resting
platelet samples, S1P levels did not differ significantly between
healthy- and diabetic-PLTs both in the absence (149 ± 6 vs.
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FIGURE 2 | Effect of platelet exposure to different pro-aggregating agents:
ADP, collagen (Coll) and arachidonic acid (AA). Platelet aggregation
parameters were higher in platelets of diabetic patients (d-PLT) than in those
of healthy subjects (h-PLT), in both platelet-rich plasma (A) or washed
platelets (B). ∗∗p < 0.005, ∗∗∗p < 0.0001 vs. h-PLT (unpaired t-test).
112± 16 ng/l, p = ns) and in the presence of collagen (171± 3 vs.
132± 21 ng/l, p = ns).
When samples were subjected to stirring, a significant increase
in S1P levels was observed in healthy-PLTs (from 149 ± 6 to
218 ± 10 ng/l, p < 0.0001) but not in diabetic-PLTs (from
112 ± 16 to 148 ± 13 ng/l, p = ns). Furthermore, S1P levels,
in stirring samples, were lower in diabetic-PLTs than in healthy-
ones both in the absence (148 ± 13 vs. 218 ± 10 ng/l, p < 0.001)
and in the presence of collagen (199 ± 6 vs. 270 ± 7 ng/l,
p < 0.0001).
ROS Levels Were Higher in Diabetic-PLTs Than in
Healthy-PLTs
To ascertain whether higher aggregation parameters
were associated with higher ROS levels, we used 2′,7′-
dihydrodichlorofluoresceine diacetate (DCF-DA) oxidation
to detect ROS intracellular concentration. As shown in
Figure 4A, there was a significantly higher ROS level in resting,
non-stimulated diabetic-PLTs than in controls (p < 0.0001).
To identify the origin of ROS, measurements were repeated
after a 20-min pre-incubation with either apocynin (APO)
or diphenyleneiodonium (DPI), two different NADPH-oxidase
inhibitors, as well as the COX-1 inhibitor, Indomethacin (INDO).
Data revealed that the basal ROS production in diabetic-PLTs
is, at least in part, mediated by the activity of NADPH-
oxidase and COX-1. In fact, with regard to baseline values,
we observed a significant decrease of ROS production in the
presence of NADPH-oxidase inhibitors, APO (p < 0.001) or
DPI (p < 0.005), and COX-1 antagonist, INDO (p < 0.001).
As expected, platelet stimulation with AA increased ROS
levels in both healthy-PLTs and diabetic-PLTs (Figure 4B).
Furthermore, diabetic-PLTs generated a significantly higher ROS
amount after stimulation with AA (6 vs. 9 fold increase,
p < 0.0001).
FIGURE 3 | S1P release in washed platelets, in resting and stirring conditions. In resting conditions, S1P levels were not different between platelets from T2DM
patients (d-PLT) and platelets from healthy subjects (h-PLT). +p < 0.05 vs. resting basal. In stirring samples, S1P levels were lower in d-PLT than in h-PLT both in the
absence and in the presence of collagen. ∗p < 0.001, ∗∗p < 0.0001 vs. healthy-PLT (unpaired t-test); #p < 0.01, ##p < 0.005 vs. corresponding stirring basal;
§ p < 0.005, §§ p < 0.001 vs. corresponding resting conditions (Newman–Keuls multiple-range test).
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FIGURE 4 | Variation of the intra-platelet level of ROS measured by DCF
fluorescence. (A) ROS level in resting platelets of diabetic patients (d-PLT)
were higher than in resting platelets of healthy subjects (h-PLT). 20-min
preincubation with apocynin (APO), diphenyleneiodonium (DPI), or
indomethacin (INDO) reduced the levels of ROS produced by d-PLT. (B) PLT
stimulation with arachidonic acid increased ROS levels in both h-PLTs and
d-PLTs. ∗∗∗p < 0.0001 vs. h-PLT; #p < 0.005, ##p < 0.001 vs. resting d-PLT
(paired t-test).
COX-1 Expression and Signaling Transduction
Molecules Were Up-Regulated in Diabetic-PLTs
We tested the hypothesis that the expression of constitutive
COX-1 was higher in diabetic-PLTs. Indeed, as shown in
Figure 5A, higher levels of COX-1 were present in diabetic-PLTs
(p < 0.0001).
We argued that phospho-AKT (pAKT) and phospho-ERK-2
levels may be enhanced by the pro-aggregating agents more in
diabetic-PLTs than in healthy-PLTs. As shown in Figure 5B,
in healthy-PLTs and diabetic-PLTs, we found similar protein
expression of AKT and ERK-2 (ERK-1 was not investigated)
(Woulfe, 2010). To evaluate the agonist-induced activation of
the PI-3K and ERK pathways, washed platelet samples were
stimulated by either collagen or AA and pAKT and pERK
level measured. As expected, the amount of pAKT increased
in response to either collagen (p < 0.0001 vs. baseline, for
both groups) or AA (p < 0.0001 vs. baseline for both groups).
However, the increase was significantly greater in diabetic-
PLTs than healthy-PLTs, for both collagen (p < 0.01) and AA
(p < 0.0001). Similarly, the amount of pERK-2 increased in
response to either collagen (p < 0.0001 vs. baseline for both
groups) or AA (p < 0.0001 vs. baseline for both groups). Yet, the
increase was greater in diabetic-PLTs than healthy-PLTs, for both
collagen (p < 0.05) and AA (p < 0.005).
Isolated Hearts
Either healthy-PLTs or diabetic-PLTs were tested in isolated rat
heart to verify their protective properties. Moreover, to ascertain
the cardioprotective pathways activated by platelets, specific
antagonists were used.
Of note, platelet infusion, as well as co-infusion with
antagonists did not affect coronary perfusion pressure and left
ventricular pressure (data not shown). These observations rule
out impaired perfusion and plugged capillaries by platelets.
Infarct Size Was Reduced by Healthy-PLTs
Pretreatment Only, via S1P Receptors and
ERK/PI3K/PKC Pathways
After I/R, in control group infarct size was 59 ± 3% of the
left ventricular mass. The 10 min pre-treatment with healthy-
PLTs significantly (p < 0.005) reduced infarct size to 47 ± 2%
of ventricular mass (Figure 6A). However, the 10 min pre-
treatment with diabetic-PLTs did not reduce infarct size, which
was 70 ± 2% of the left ventricular mass (Not Significant vs. I/R
group; p < 0.005 vs. healthy-PLT group).
To study the role of myocardial S1P receptors and RISK
pathway, healthy-PLTs were alternatively co-infused with one
of the following compounds: VPC23019 to block cardiac S1P
Receptors (types 1 and 3), U0126 to inhibit ERK1/2, LY294002
to inhibit PI3K, or Chelerythrine to block PKC. At the end of
reperfusion, in these four inhibitor groups, infarct sizes (66± 2%,
61 ± 2%, 61 ± 3%, and 63 ± 3% of the ventricular mass,
respectively) were similar to those observed in control I/R hearts,
but significantly (p < 0.005 for all) higher than in healthy-PLTs
group (Figure 6B).
The infusion of antagonists alone (VPC23019, U0126,
LY294002, or Chelerythrine) did not affect infarct size, which
was similar to control group (63 ± 2%, 59 ± 2%, 70 ± 5%, and
65± 3%, respectively, data not reported in the figure). These data
are in agreement with previous studies (Penna et al., 2005; Vessey
et al., 2009; Mochizuki et al., 2013).
Diabetic Platelet ROS Levels Correlate With Infarct
Size
We hypothesized a correlation between platelet ROS levels (an
index of platelet dysfunction) and infarct size. Indeed Figure 6C
displays a good correlation between platelet ROS levels and
infarct size for data of diabetic-PLTs, whereas between ROS levels
in healthy-PLTs and infarct size there is a poor, not significant,
correlation (Figure 6D).
Myocardial Phospho-ERK Is Involved in Healthy-PLT
Induced Cardioprotection
To corroborate data obtained with inhibitors of survival
kinases, we measured ERK-1/2 expression and phosphorylation
in myocardial tissue of hearts treated with healthy-PLTs.
The phosphorylation of ERK-1/2 was greater in hearts pre-
treated with healthy-PLTs compared to hearts subjected to I/R
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FIGURE 5 | Protein content in platelets determined by Western blot. (A) Cyclooxygenase-1 (COX-1) levels were higher in platelets of diabetic patients (d-PLT) than in
those of healthy subjects (h-PLT). (B) Phosphorylated Protein Kinase B (pAKT) and Phosphorylated Extracellular Signal-regulated Kinase-2 (pERK-2) were increased
by collagen (Coll) and arachidonic acid (AA) stimulation in both h-PLT and d-PLT. However, the increases were higher in d-PLTs than in h-PLTs. ###p < 0.0001 vs.
basal level; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.0001 vs. h-PLT (unpaired t-test and Newman–Keuls multiple-range test).
(p < 0.0001; Figure 7). A three–fourfold higher pERK/total ERK
ratio was observed in healthy-PLT pretreated hearts compared
to I/R hearts. In diabetic-PLT pretreated hearts the ratio was not
different from that in I/R hearts.
DISCUSSION
The main novel findings of this study are: (1) the heart
pretreatment with platelets of healthy humans (healthy-
PLTs) reduces infarct size, (2) the cardioprotective properties
of healthy-PLTs depend on myocardial S1P receptor and
RISK (PI3K-ERK-1/2-PKC) pathway activation, (3) the
cardioprotective properties are lost by platelets from T2DM
patients (diabetic-PLTs), which release less S1P than healthy-
PLTs after mechanical and chemical stimulation, in vitro, and (4)
the higher is the ROS level in PLTs the higher is infarct size in
hearts pretreated with diabetic PLTs.
Pretreatment With Healthy Human PLTs
Reduces Infarct Size via S1P Receptor
Activation
Pre-treatment with healthy human PLTs limits infarct size in
the Langendorff isolated rat heart. Thus, platelets may interact
with uninjured organ to trigger protection in hearts subsequently
subjected to I/R ex vivo. Data are in agreement with previous
studies showing that perfusion of isolated rat hearts with platelets
from normal rats protects against myocardial dysfunction caused
by I/R, improving both biochemical and dynamic cardiac
parameters (Yang et al., 1993, 1994; Yang and Mehta, 1994;
Mehta et al., 1999). Similar cardioprotection was observed in
hearts perfused with platelet supernatant (Yang et al., 1998,
1999), thus suggesting an important role for factors released by
platelets.
In our model, the treatment of hearts with VPC23019, an
S1PR1 and S1PR3 antagonist (Davis et al., 2005), abrogates
cardioprotection induced by healthy-PLTs. Therefore, it is likely
that healthy human platelets protect the hearts against I/R injury
via an S1P mediated mechanism. Indeed, S1P is a platelet factor
whose release originates from two pools: one constitutively
secreted and located at the plasma membrane, and the other
rapidly phosphorylated upon stimulation and mobilized from
granules (Yatomi et al., 1995; Tani et al., 2005). This release in the
supernatant is influenced by mechanical (stirring) and chemical
(collagen) stimuli in vitro.
Intriguingly, S1P is a crucial signal molecule abundantly
stored in platelets, which displayed a variety of cellular functions,
including cardioprotective properties (Chalfant and Spiegel,
2005; Cohen et al., 2016). S1P is stored within the platelets
and is released in certain circumstances (Tani et al., 2005).
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FIGURE 6 | Infarct size expressed as percent of area at risk (A,B), and platelet ROS-infarct size correlations (C,D). (A) Washed platelets derived from healthy
subjects (h-PLT) limited infarct size. The infarct size in hearts treated with platelets derived from diabetic patients (d-PLT) was higher than that observed in hearts
pretreated with h-PLT. (B) The infarct size limitation effects of h-PLTs was abrogated by the blocker of S1P receptors, VPC23019, the antagonist of ERK1/2, U0126,
the inhibitor of PI3K, LY or the antagonist of PKC, CHE. ∗p < 0.005 vs. h-PLT; #p < 0.005 vs. I/R; NS, not significant (Newman–Keuls multiple-range test).
(C) Correlation between ROS platelet levels and infarct size for the d-PLT group (n = 7; linear regression). (D) correlation between ROS platelet levels and infarct size
for the h-PLT group (n = 7; linear regression).
Several studies performed in animal and in vitro models have
proposed that S1P possesses cardioprotective effects (Kupperman
et al., 2000; Jin et al., 2002; Zhang et al., 2007; Karliner, 2013;
Maceyka and Spiegel, 2014). Moreover, S1P protects cultured
rat neonatal cardiomyocytes from ischemia-induced cell death
(Jin et al., 2002; Karliner, 2013). Since only S1PR1, S1PR2, and
S1PR3 are the receptor subtypes expressed in cardiac myocytes
and endothelial cells (Peters and Alewijnse, 2007; Karliner, 2009;
Means and Brown, 2009; Zhang et al., 2013), it is likely that
these receptors play a major role in cardioprotection by healthy-
PLT pretreatment. Indeed, in the heart binding of S1P to S1PR1
leads to activation of ERK1/2 and binding to the S1PR3 receptor
promotes the activation of PI3K/AKT (Knapp, 2011; Somers
et al., 2012). Nevertheless, it is likely that the cardioprotective
effect of S1P is the result of a co-operation of the three receptors
expressed by the heart (Means et al., 2007; Vessey et al., 2009;
Cohen et al., 2016). That is why blocking both S1PR1 and
S1PR3 with VPC23019, we blocked the platelet cardioprotective
effects. It is unlikely that VPC23019 interfered with platelet S1P
receptors because platelets express mainly S1PR2 and S1PR4
(Randriamboavonjy et al., 2009; Onuma et al., 2017) (see also
below “Methodological considerations and limitations of the
study”).
Infarct Size Limitation by Healthy-PLTs Is
Reversed by RISK (PI3K, ERK-1/2, and
PKC) Pathway Inhibition
It has been reported that nitric oxide release may mediate
cardioprotection by S1P (Egom et al., 2011). Since in the
RISK pathway AKT is upstream to nitric oxide synthase,
we verified whether inhibitors of RISK pathway may avoid
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FIGURE 7 | Phosphorylation of extracellular signal-regulated kinases (ERK-1/2) in lysates from hearts subjected to I/R only (control) or pre-treated with d-PLTs
(washed platelets derived from diabetic patients) or h-PLTs (washed platelets derived from healthy subjects). Representative western blot of ERK-1/2
phosphorylation and total ERK-1/2 of protein extract from control I/R (n = 4), d-PLTs (n = 5), and h-PLTs (n = 8) hearts. Histograms represent the ratio of
phosphorylated over total ERK protein expression. Data suggest that pretreatment with h-PLTs induces an increase in ERK-1/2 phosphorylation with respect to I/R
only. ∗P < 0.0001 vs. I/R; #P < 0.001 vs. d-PLTs (Newman–Keuls multiple-range test).
FIGURE 8 | Schematic representation of the intracellular pathway involved in
the platelet/S1P cardioprotection.
platelet-induced cardioprotection. Indeed, healthy-PLT-induced
cardioprotection was completely abolished by pre-treating the
heart with LY294002 to block PI3K, or Chelerythrine to
block PKC, as well as U0126 to inhibit ERK-1/2. Thus,
suggesting a pivotal role of these survival kinases in the
platelet-induced cardioprotection (Figure 8). A role which
is corroborated by myocardial Western blot data, revealing
elevated levels of pERK-1/2 in healthy-PLT pretreated hearts
only. This kinase phosphorylation is usually observed in
conditioning treatments, with a peak of the pERK/total
ERK ratio 10–15 min after the end of ischemia and a
progressive reduction thereafter (Ferdinandy et al., 2014;
Penna et al., 2014; Cohen and Downey, 2015). A three–
fourfold higher pERK/total ERK ratios in hearts pretreated with
healthy-PLTs is a strong indication of kinase involvement in
protection, especially if we consider that healthy-PLT pretreated
hearts have just a 30% more vital tissue than control I/R
hearts.
Moreover, since STAT3 seems to be downstream to ERK
(Knapp, 2011; Somers et al., 2012) in ongoing experiments
we tested whether healthy or diabetic PLTs can activate
myocardial STAT3. Indeed, we found that h-PLT treated hearts
display a higher pSTAT3 level than d-PLT treated hearts (see
Supplementary Materials).
However, it has been also shown that in some circumstances,
platelets may contribute to initiation and propagation of
I/R myocardial injury (Aiken et al., 1981; Vanhoutte and
Houston, 1985; Yee et al., 1986; Patel et al., 2001; Seligmann
et al., 2013). These apparently conflicting reports may reflect
different experimental designs: platelets introduced into the
coronary system of heart preparations not before but during
or after ischemia, atherosclerotic coronary arteries or coronary
endothelial barrier failure. In particular, it has been suggested
that the deleterious effects of platelets on reperfused myocardium
depend on their activation status, which is enhanced by
the previous exposure to I/R injured myocardium (Mirabet
et al., 2002). In other words, it seems that in I/R scenario
platelet deleterious effects are due to interaction with injured
tissues and/or platelet pre-activation. Therefore, we studied the
“hyperreactive” diabetic-PLTs.
Cardioprotective Properties Are Lost by
Diabetic-PLTs
The cardioprotective properties seen for healthy-PLTs are
lost by diabetic-PLTs. In fact, infarct size after intracoronary
pretreatment with diabetic-PLTs is significantly higher than
that observed in hearts pre-treated with healthy-PLTs and not
significantly different from the control I/R hearts. This is
in agreement with the idea that activated platelets lose the
cardioprotective properties (Mirabet et al., 2002).
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Multiple factors may cause dysregulation of platelet signaling
pathways leading to a hyper-reactive platelet phenotype. Indeed,
diabetic subjects of our study were not only characterized by
hyperglycemia and uncontrolled diabetes but also by other
dysmetabolic conditions such as obesity and dyslipidemia,
commonly associated with T2DM, and each of them may
contribute to the diabetic-PLT hyper-reactivity observed in
this population (Russo, 2012; Morange and Alessi, 2013). In
this study, we confirm that, in comparison with healthy-PLTs,
platelets from T2DM patients show: (a) higher aggregating
response to agonists (b) higher basal and AA-induced production
of ROS, (c) enhanced levels of COX-1 and (d) increased
levels of phospho-AKT and phospho-ERK-2 upon stimulation
with agonists, more in diabetic than healthy platelets, thus
confirming the hyper-reactivity of diabetic platelets. However,
unlike myocardium, these two kinases are not linked to
a survival signaling in platelets (Kovacsovics et al., 1995;
Aharonovitz and Granot, 1996). Indeed, following stimuli, ERK
and AKT regulate platelet activation and function, such as
adhesion or secretory changes, and are actively involved in
conveying signals from several pathways leading to platelet
activation (Kovacsovics et al., 1995; Aharonovitz and Granot,
1996).
Our findings on platelet function in T2DM subjects fit
into the general picture of the current research that describes
platelet hyper-reactivity as responsible, at least in part, of the
prothrombotic state in T2DM (Jung et al., 2015). We also
demonstrate that higher ROS levels in diabetic-PLTs are, at
least in part, due to enhanced production by NADPH-oxidase
and COX-1 activity. Indeed, ROS generation in diabetic-PLTs is
mostly produced by COX-1 activity, as shown by the significant
reduction of ROS levels using the COX-1 inhibitor, INDO. A role
is also played by the pro-oxidant enzyme NADPH-oxidase, as
shown by the significant reduction of ROS levels when diabetic-
PLTs were preincubated with two different NADPH-oxidase
inhibitors, APO or DPI. Several reports have suggested that
ROS represent a new modulator of platelet activity and ROS
generated by platelets have a direct role in the control of their
responsiveness (Vazzana et al., 2012).
The correlation between platelet ROS levels in diabetic
platelets and the extension of infarct size suggests that the redox
status in these platelets may play a pivotal role in influencing their
cardiac effects. The absence of correlation for healthy platelets
suggests that a certain threshold of ROS should be reached
to affect protective properties. Of note, a complete prevention
of the post-ischemic cardio-depressive effects by platelets –
administrated during ischemia or reperfusion on isolated guinea
pig hearts – was observed after platelet pretreatment with the
NADPH-oxidase inhibitor, DPI (Seligmann et al., 2013). These
data are in agreement with our data that ROS levels in hyperactive
platelets are correlated to the extension of I/R injury and that
platelet ROS derive, at least in part, from NADPH-oxidase.
Nevertheless, correlation is not causality and our results need
further studies to clarify the role of ROS.
Here, we show that diabetic platelets release less S1P when
mechanically (stirring) or chemically (collagen) stimulated. Our
findings are in line with the observation that diabetic platelets
have a dysregulation of the S1P component ready to be mobilized
(Ksia˛z˙ek et al., 2015). Moreover, the fact that S1P release is
compromised is in agreement with the observation that diabetic
platelets display higher expression of signs and factors of
dysregulation, including higher ROS amount produced at basal
condition and after stimulation with AA. In other words, the
loss of protective properties observed in diabetic platelets could
be linked to the altered redox and aggregatory conditions of
these platelets that would alter the modality and/or quantity of
released S1P. However, this hypothesis needs more experiments
to be fully ascertained. Also, the consequences and mechanisms
of S1P dysregulation in diabetic platelets need to be further
investigated.
Methodological Considerations and
Limitations of the Study
The main aim of the present study was to ascertain the
mechanisms of platelet-induced cardioprotection. However,
diabetic PLTs were not protective and it remains to ascertain
the reasons for this ineffectiveness. Indeed, the use of a normal
heart allowed us to rule out that the lack of protection is
due to myocardial resistance to protection, typical of diabetes
and other co-morbidities (Ferdinandy et al., 2014). The defect
is likely within diabetic platelets: the impaired release of S1P
may prevent protection from diabetic-PLTs. However, it cannot
be so easily determined because these platelets are ineffective
in influencing the infarct size in Langendorff hearts: blocking
myocardial S1P receptors or RISK pathway will not reveal
the mechanism of diabetic-PLTs ineffectiveness. It may be
also argued that blocking ROS production with antioxidants
in washed platelets may reverse the platelet defect but ROS
blockers/scavengers may interfere directly with myocardial I/R
injury and/or platelet S1P release. Therefore, future studies
should envision appropriate protocols to solve these open
questions and, in particular, the reasons for diabetic-PLTs
ineffectiveness.
Although the Langendorff ’s model, like all experimental
paradigms, has disadvantages and advantages, it is a useful
paradigm for studying the role of cardioprotective procedures
(Bell et al., 2011). Indeed, Langendorff ’s model allows to
subjecting the heart to a “clean” test, and to remove unwanted
interferences by blood cells, protein and other “confounding
variables,” such as temperature, perfusion, and neuro-hormonal
influences. Indeed, experiments performed on Langendorff ’s
murine model provided very strong data on the cardioprotective
effect of S1P (Jin et al., 2002; Lecour et al., 2002; Vessey et al.,
2006, 2008).
It is unlikely that the S1PR1/3 antagonist, VPC23019,
interfered with the capacity of platelets to release S1P. It has
been reported that human platelets may express types 1, 2,
and 4 of S1PRs (Hla et al., 2012; Urtz et al., 2015). However,
Fleming and co-workers were able to detect S1PR2, but not
S1PR1 on human platelets (Randriamboavonjy et al., 2009); in
this study, S1PR2 displayed a pro-aggregating role. In another
study, it has been suggested that S1P suppresses collagen-induced
aggregation via S1PR4, but not through S1PR1 in human platelets
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(Onuma et al., 2017). Therefore, it seems that human platelets
express S1PR2 and S1PR4, with a pro- and anti-aggregant role,
respectively. Whether S1PR1 is present and/or play a role seems
controversial. Therefore, VPC23019 may not interfere with the
principal receptors present on platelets, but it is specific for the
receptors expressed by the cardiac tissues. Nevertheless, S1PRs
are involved in platelet-induced cardioprotection.
We used a commercially available ELISA kit for the assessment
of S1P release in washed platelets. This differs from protocol
usually performed to measure S1P levels in serum or plasma
samples where high-density lipoproteins are the major plasma
carriers for S1P. Clearly, S1P values in our study are not
comparable to those obtained in blood/plasma samples.
We used washed platelets, therefore it is unlikely that the
S1P was already in the perfusate. Only the S1P released by
circulating platelets may be involved in the cardioprotective
effect. Indeed, stirring may simulate the circulating conditions
that allow the release of larger quantities of S1P. Nevertheless, in
future studies, it might be worthwhile to test whether platelet-
derived supernatant can be protective via S1P mechanism.
In summary, three key observations regarding the platelet
function and role in I/R scenario were made in this study: (1)
S1P/S1PRs play important roles in determining healthy-platelet-
induced cardioprotection via myocardial RISK pathway, in an
isolated rat heart model, (2) these cardioprotective properties are
lost by diabetic platelets, which produce higher levels of ROS and
lower levels of S1P when stimulated in vitro, and (3) infarct size
correlates with the amount of ROS produced by diabetic platelets.
CONCLUSION
Here we provide evidence that human healthy platelets
exert cardioprotective effects via activation of an S1P related
mechanism. It is likely that myocardial RISK pathway plays
a pivotal role in platelet-induced cardioprotection. Our data
also suggest that alterations in ROS production and in S1P
release may be involved in the impairment of function and
the loss of cardioprotective properties by diabetic platelets.
Since plasma S1P concentration is reduced in patients with
myocardial infarction (Knapp et al., 2009), its modulation by
drugs targeting platelets might be very important and need to be
better understood. Since exosomes greatly contribute to platelet
activity, whether and how the platelet-induced cardioprotection
is linked to the well-known exosome-induced cardioprotection
(Barile et al., 2014, 2018) remain to be elucidated. Further studies
in this direction are warranted.
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FIGURE S1 | Expression of extracellular signal-regulated kinases (ERK-1/2) in
lysates from hearts subjected to ischemia/reperfusion only (I/R) or pre-treated with
platelets from healthy subjects (hPLT+IR).
FIGURE S2 | Phosphorylation of extracellular signal-regulated kinases (pERK-1/2)
in lysates from hearts subjected to ischemia/reperfusion only (I/R) or pre-treated
with platelets from healthy subjects (hPLT+IR).
FIGURE S3 | Expression of protein kinase B (AKT) in platelets from healthy and
Type 2 Diabetes Mellitus (T2DM) subjects in the absence (basal) or in the presence
of collagen (coll) or arachidonic acid (AA).
FIGURE S4 | Expression of ciclooxygenase-1 (COX-1) in platelets from healthy
and Type 2 Diabetes Mellitus (T2DM) subjects.
FIGURE S5 | Expression of extracellular signal-regulated kinase-2 (ERK-2) in
platelets from healthy and Type 2 Diabetes Mellitus (T2DM) subjects in the
absence (basal) or in the presence of collagen (coll) or arachidonic
acid (AA).
FIGURE S6 | Phosphorylation of protein kinase B (pAKT) in platelets from healthy
and Type 2 Diabetes Mellitus (T2DM) subjects in the absence (basal) or in the
presence of collagen (coll) or arachidonic acid (AA).
FIGURE S7 | Phosphorylation of extracellular signal-regulated kinases (pERK-1/2)
in platelets from healthy and Type 2 Diabetes Mellitus (T2DM) subjects in the
absence (basal) or in the presence of collagen (coll) or arachidonic acid (AA).
FIGURE S8 | Expression of vinculin in platelets from healthy and Type 2 Diabetes
Mellitus (T2DM) subjects.
FIGURE S9 | Expression of extracellular signal-regulated kinases (ERK-1/2) in
lysates from hearts subjected to ischemia/reperfusion only (I/R), pre-treated with
platelets from Type 2 Diabetes Mellitus (T2DM) subjects (dPLT+IR) or healthy
(hPLT+IR).
FIGURE S10 | Phosphorylation of extracellular signal-regulated kinases
(pERK-1/2) in lysates from hearts subjected to ischemia/reperfusion only (I/R),
pre-treated with platelets from Type 2 Diabetes Mellitus (T2DM) subjects
(dPLT+IR) or healthy (hPLT+IR).
FIGURE S11 | Phosphorylation of STAT-3 (pSTAT-3) in lysates from hearts
subjected to ischemia/reperfusion only (I/R), pre-treated with platelets from healthy
(hPLT+IR) or Type 2 Diabetes Mellitus (T2DM) subjects (dPLT+IR).
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